USA - New York Stock Exchange - NYSE:HNGE - US4333131039 - Common Stock
The current stock price of HNGE is 49.73 USD. In the past month the price increased by 10.25%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.53 | 100.28B | ||
| CI | THE CIGNA GROUP | 9.29 | 70.51B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 118.23 | 21.75B | ||
| LH | LABCORP HOLDINGS INC | 16.35 | 21.44B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.42 | 20.00B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.32B | ||
| HIMS | HIMS & HERS HEALTH INC | 73.87 | 9.08B | ||
| DVA | DAVITA INC | 12.62 | 8.22B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 34.3 | 6.31B | ||
| RDNT | RADNET INC | 200.45 | 5.88B | ||
| CHE | CHEMED CORP | 19.02 | 5.92B | ||
| OPCH | OPTION CARE HEALTH INC | 21.5 | 5.08B |
Hinge Health, Inc. is a digital healthcare company, which engages in software for joint and muscle health care. The company is headquartered in San Francisco, California and currently employs 1,514 full-time employees. The company went IPO on 2025-05-22. The firm has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. The company offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.
HINGE HEALTH INC-A
455 Market Street, Suite 700
San Francisco CALIFORNIA US
Employees: 1514
Phone: 14156898429
Hinge Health, Inc. is a digital healthcare company, which engages in software for joint and muscle health care. The company is headquartered in San Francisco, California and currently employs 1,514 full-time employees. The company went IPO on 2025-05-22. The firm has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. The company offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.
The current stock price of HNGE is 49.73 USD. The price increased by 1.39% in the last trading session.
HNGE does not pay a dividend.
HNGE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
21 analysts have analysed HNGE and the average price target is 65.57 USD. This implies a price increase of 31.85% is expected in the next year compared to the current price of 49.73.
HINGE HEALTH INC-A (HNGE) has a market capitalization of 3.91B USD. This makes HNGE a Mid Cap stock.
The outstanding short interest for HINGE HEALTH INC-A (HNGE) is 13.95% of its float.
ChartMill assigns a technical rating of 5 / 10 to HNGE.
ChartMill assigns a fundamental rating of 4 / 10 to HNGE. HNGE has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months HNGE reported a non-GAAP Earnings per Share(EPS) of -14.4. The EPS increased by 88.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.87% | ||
| ROE | -165.85% | ||
| Debt/Equity | 0 |
21 analysts have analysed HNGE and the average price target is 65.57 USD. This implies a price increase of 31.85% is expected in the next year compared to the current price of 49.73.
For the next year, analysts expect an EPS growth of 635.95% and a revenue growth 49.92% for HNGE